Remepy

📍 New York, United States🗓 Founded 2022👥 64 employees💰 Last funded Jun 2023
Biotechnology Research🌐 remepy.com
Website LinkedIn
Remepy is Pioneering Hybrid Drugs™. Many medical conditions are better treated by combining pharmaceutical and non-pharmaceutical treatments. Hybrid drugs are a new type of drug asset, that combines traditional drugs with proprietary treatment protocols delivered measured and adapted using our AI capabilities. Remepy’s Digital Molecules™ are designed to be the software apps within Hybrid Drugs™. They are based on digital interventions and treatment protocols that are tailored to each medical condition and its corresponding drug and are constantly measured and tracked and personalized using advanced AI capabilities. The Digital Molecules™ enhance brain functions that balance the patients neuro-endocrine and neuro-immunological systems and boost brain neuroplasticity, in order to optimize drug performance. We also address physical, motor, psychological, and behavioral symptoms Remepy partners with pharma companies to bring Hybrid Drugs™ to market that will combine Remepy’s Digital Molecule™ and traditional drug components.
5
Total investors
5
Early stage
0
Mid stage
0
Late stage
2022
Founded

Investors

5 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Israel
4
United States
1
Investor activity2022–2023 · investors recorded per year
2022220233
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Remepy?
Remepy has 5 investors on record on gritt.io, including 5 early-stage backers.
When did Remepy last raise funding?
The most recent investment in Remepy recorded on gritt.io was in June 2023.
When was Remepy founded?
Remepy was founded in 2022.
What industry is Remepy in?
Remepy operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Remepy based?
Remepy is headquartered in New York, United States.